158 related articles for article (PubMed ID: 25820046)
1. Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients.
Shetty SR; Kumar S; Mathur RP; Sharma KH; Jaiswal AD
Indian Heart J; 2015; 67(1):23-6. PubMed ID: 25820046
[TBL] [Abstract][Full Text] [Related]
2. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
Kaul U; Parmar D; Manjunath K; Shah M; Parmar K; Patil KP; Jaiswal A
Cardiovasc Diabetol; 2019 Jun; 18(1):80. PubMed ID: 31208414
[TBL] [Abstract][Full Text] [Related]
3. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
Krishnappa M; Patil K; Parmar K; Trivedi P; Mody N; Shah C; Faldu K; Maroo S; ; Parmar D
Cardiovasc Diabetol; 2020 Jun; 19(1):93. PubMed ID: 32560724
[TBL] [Abstract][Full Text] [Related]
4. Saroglitazar for the treatment of dyslipidemia in diabetic patients.
Joshi SR
Expert Opin Pharmacother; 2015 Mar; 16(4):597-606. PubMed ID: 25674933
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI).
Jani RH; Pai V; Jha P; Jariwala G; Mukhopadhyay S; Bhansali A; Joshi S
Diabetes Technol Ther; 2014 Feb; 16(2):63-71. PubMed ID: 24138536
[TBL] [Abstract][Full Text] [Related]
6. Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes.
Chatterjee S; Majumder A; Ray S
Sci Rep; 2015 Jan; 5():7706. PubMed ID: 25573251
[TBL] [Abstract][Full Text] [Related]
7. The first approved agent in the Glitazar's Class: Saroglitazar.
Agrawal R
Curr Drug Targets; 2014 Feb; 15(2):151-5. PubMed ID: 23906191
[TBL] [Abstract][Full Text] [Related]
8. Study of Saroglitazar in Treatment Of Pre-diabetes with Dyslipidemia: STOP-D.
Bhosle D; Bhosle V; Bobde J; Bhagat A; Shaikh H; Kadam R
J Assoc Physicians India; 2018 Mar; 66(3):14-7. PubMed ID: 30341861
[TBL] [Abstract][Full Text] [Related]
9. Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study.
Rastogi A; Dunbar RL; Thacker HP; Bhatt J; Parmar K; Parmar DV
Acta Diabetol; 2020 Jul; 57(7):809-818. PubMed ID: 32030508
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study.
Rajesh NA; Drishya L; Ambati MMR; Narayanan AL; Alex M; R KK; Abraham JJ; Vijayakumar TM
J Clin Exp Hepatol; 2022; 12(1):61-67. PubMed ID: 35068786
[TBL] [Abstract][Full Text] [Related]
11. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study.
Goyal O; Nohria S; Goyal P; Kaur J; Sharma S; Sood A; Chhina RS
Sci Rep; 2020 Dec; 10(1):21117. PubMed ID: 33273703
[TBL] [Abstract][Full Text] [Related]
12. Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial.
Jain N; Bhansali S; Kurpad AV; Hawkins M; Sharma A; Kaur S; Rastogi A; Bhansali A
Sci Rep; 2019 Dec; 9(1):19017. PubMed ID: 31831868
[TBL] [Abstract][Full Text] [Related]
13. Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis.
Siddiqui MS; Parmar D; Sheikh F; Sarin SK; Cisneros L; Gawrieh S; Momin T; Duseja A; Sanyal AJ
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2597-2605.e2. PubMed ID: 36731585
[TBL] [Abstract][Full Text] [Related]
14. A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia.
Balakumar P; Mahadevan N; Sambathkumar R
Curr Mol Pharmacol; 2019; 12(3):195-201. PubMed ID: 30636619
[TBL] [Abstract][Full Text] [Related]
15. A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy.
Deshpande A; Toshniwal H; Joshi S; Jani RH
PLoS One; 2016; 11(1):e0146222. PubMed ID: 26789842
[TBL] [Abstract][Full Text] [Related]
16. Clinical Case Series of Decrease in Shear Wave Elastography Values in Ten Diabetic Dyslipidemia Patients Having NAFLD with Saroglitazar 4 mg: An Indian Experience.
Roy S
Case Rep Med; 2020; 2020():4287075. PubMed ID: 32280349
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: A meta-analysis.
Dutta D; Bhattacharya S; Surana V; Aggarwal S; Singla R; Khandelwal D; Sharma M
Diabetes Metab Syndr; 2020; 14(6):1759-1768. PubMed ID: 32937280
[TBL] [Abstract][Full Text] [Related]
18. A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V).
Pai V; Paneerselvam A; Mukhopadhyay S; Bhansali A; Kamath D; Shankar V; Gambhire D; Jani RH; Joshi S; Patel P
J Diabetes Sci Technol; 2014 Jan; 8(1):132-141. PubMed ID: 24876549
[TBL] [Abstract][Full Text] [Related]
19. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
Gawrieh S; Noureddin M; Loo N; Mohseni R; Awasty V; Cusi K; Kowdley KV; Lai M; Schiff E; Parmar D; Patel P; Chalasani N
Hepatology; 2021 Oct; 74(4):1809-1824. PubMed ID: 33811367
[TBL] [Abstract][Full Text] [Related]
20. An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Mitra A
Cureus; 2020 Jul; 12(7):e9065. PubMed ID: 32782883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]